HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plaintiff Puts ‘Clean Beauty’ To Test In Federal Court In Sephora USA Case

Executive Summary

The class action complaint in New York federal court suggests a parity between “clean” and natural claims in the understanding of beauty consumers.

You may also be interested in...



‘Clean At Sephora’ Suit Fails Reasonable Consumer Test; Case Dismissed

Sephora successfully dismissed a putative class action in New York’s Northern District on 15 March, as the judge was not convinced by the plaintiff that a reasonable consumer would read “Clean at Sephora” as meaning “no synthetic or harmful ingredients whatsoever.”

Sephora Well-Positioned To Defend ‘Clean Beauty’ Case, Attorney Says

Sephora USA is in a strong position to defend its ‘Clean at Sephora’ designation for certain products because it is transparent about what the claim means, and the plaintiff in the case may not be able to show that a reasonable consumer would be misled, says Angela Diesch, partner in the Los Angeles office of Amin Talati Wasserman, LLP.

Sephora Asks NY Federal Court To Toss Out ‘Clean at Sephora’ False Advertising Suit

The beauty retailer moves to dismiss a putative class action targeting its ‘Clean at Sephora’ designation for products sold on its website, maintaining its program is a model of transparency. Allowing the case to move forward would “leave no word safe from linguistic manipulation,” Sephora says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel